Accuray Inc. (ARAY), a prominent radiation therapy company, announced on Wednesday that the Chinese National Medical Products Administration (NMPA) has approved the registration dossier for the Accuray Precision Treatment Planning System (TPS).
With this approval, the Accuray Precision TPS is now integrated for use with the CNNC-Accuray joint venture Tomo C radiation therapy system. This system offers medical teams a new capability for delivering highly precise and accurate radiotherapy treatments.
Accuray highlighted that the system was designed to streamline the creation and adaptation of detailed treatment plans in less time.
"We are thrilled about the approval of the Accuray Precision Treatment Planning System and the significant potential it offers, especially when combined with the Tomo C System, for cancer patients in China," stated Suzanne Winter, President and CEO of Accuray. "China accounted for approximately 25 percent of new cancer cases diagnosed worldwide in 2020. With this approval, our China joint venture can commence shipping the Tomo C System to their end customers, marking a crucial step forward in addressing the unmet need for precision radiation therapy."
For more health news, visit rttnews.com.
